Get startedLog in
    Picture of AbbVie logo

    ABBV — AbbVie News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Abbvie - Q3 2026 GAAP And Adjusted Earnings Include $216 Million Bought Ipr&D And Milestones Expense - SEC Filing

    Picture of AbbVie logoAbbVie
    05/10/2026 23:09
    BRIEF-Abbvie - Q3 2026 GAAP And Adjusted Earnings Include $216 Million Bought Ipr&D And Milestones Expense - SEC Filing
    Oct 5 (Reuters) - AbbVie Inc. ABBV.N:
    • ABBVIE - Q3 2026 GAAP AND ADJUSTED EARNINGS INCLUDE $216 MILLION BOUGHT IPR&D AND MILESTONES EXPENSE - SEC FILING
    • ABBVIE - FULL-YEAR 2026 ADJUSTED DILUTED EPS GUIDANCE RANGE INCLUDING BOUGHT IPR&D IS $13.76-$13.96 - SEC FILING
    • ABBVIE - Q3 2026 ADJUSTED DILUTED EPS GUIDANCE RANGE INCLUDING BOUGHT IPR&D IS $3.73-$3.77 - SEC FILING
    • FY2026 EARNINGS PER SHARE VIEW $14.02 -- LSEG IBES DATA
    • Q3 EARNINGS PER SHARE VIEW $3.84 -- LSEG IBES DATA
    • ABBVIE - BOUGHT IPR&D AND MILESTONES EXPENSE IMPACTS Q3 GAAP AND ADJUSTED DILUTED EPS BY $0.11 - SEC FILING
    Source text: [ID:n0001551152-26-000030]
    Further company coverage: ABBV.N

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on AbbVie

    See all news